VivoSim Labs FY 2026 Loss Widens to $13.84M as Revenue Stalls at $0.13M
VIVS is trading near its 52-week low of $0.78 (11% above the low).
Summary
VivoSim Labs reported FY 2026 revenue of just $0.13M, essentially flat year-over-year, while net loss ballooned to $13.84M from $2.49M in FY 2025. The loss per share of $(5.35) compares to $(1.70) last year. The company has a going concern warning and a stockholders' deficit that breaches Nasdaq's minimum equity rule, with cash insufficient to fund the next year. A $5M milestone payment received in July 2026 from the FXR program sale provides some runway, but the core toxicology services business has yet to generate meaningful revenue. Management cut R&D spending by 17% and reduced headcount to conserve cash. The 10-K filing confirms the precarious financial position; the next milestone or service contract win is critical to avoid delisting or a dilutive financing.
At the time of this announcement, VIVS was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.78 to $5.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.